Speaking of Advent AML - there has been a change this week:
https://clinicaltrials.gov/study/NCT05834244?term=NCT05834244&rank=1&tab=history&a=7&b=8#version-content-panelIntermediate risk
People in this group have genetic and chromosomal changes that do not fit easily into the favourable and adverse groups. Doctors may look at other factors such as age and overall health to decide on treatment. People usually have chemotherapy. They may then have more intense treatment depending on their situation.
Adverse risk
People in this risk group have a greater risk of their leukaemia coming back (relapsing) or not responding to treatment. They usually have more intense treatment. For example, high dose chemotherapy followed by a donor stem cell transplant. They may have treatment as part of a clinical trial.
https://www.cancerresearchuk.org/about-cancer/acute-myeloid-leukaemia-aml/types-aml
Fair to say that broadening the patient pool is likely based on the dose finding cohort which completed enrolment end of October.
Preliminary data soon-ish?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $28.14K | 7.037M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 243067 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 14771167 | 22 |
View Market Depth
| Last trade - 15.39pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |